Teresa L Jacobs1, Devin L Brown2, Jonggyu Baek2, Erin M Migda2, Timothy Funckes2, Kirsten L Gruis2. 1. From the Departments of Neurosurgery (T.L.J.) and Neurology (T.L.J., D.L.B., E.M.M., T.F.), University of Michigan; Biostatistics (J.B.), University of Michigan School of Public Health, Ann Arbor; and Idera Pharmaceuticals (K.L.G.), Cambridge, MA. teresmit@umich.edu. 2. From the Departments of Neurosurgery (T.L.J.) and Neurology (T.L.J., D.L.B., E.M.M., T.F.), University of Michigan; Biostatistics (J.B.), University of Michigan School of Public Health, Ann Arbor; and Idera Pharmaceuticals (K.L.G.), Cambridge, MA.
Abstract
OBJECTIVE: To evaluate the use and tolerability of noninvasive positive pressure ventilation (NIV) in patients with amyotrophic lateral sclerosis (ALS) early in their disease by comparing active NIV and sham NIV in patients not yet eligible for NIV use as recommended by practice guidelines. METHODS: This was a single-center, prospective, double-blind, randomized, placebo (sham)-controlled pilot trial. Patients with ALS were randomized to receive either sham NIV or active NIV and underwent active surveillance approximately every 3 months until they reached a forced vital capacity (FVC) <50% or required NIV for clinical symptom management. RESULTS: In total, 54 participants were randomized. The mean NIV use was 2.0 hours (95% confidence interval [CI] 1.1-3.0) per day in the sham NIV treatment group and 3.3 hours (CI 2.0-4.6) per day in the active NIV group, which did not differ by treatment group (p = 0.347). The majority of sham NIV participants (88%) and active NIV participants (73%) reported only mild or no problem with NIV use. Difference of change in FVC through the treatment period by group (0.44 per month) favored active NIV (p = 0.049). Survival and changes in maximal inspiratory or expiratory pressure did not differ between treatment groups. CONCLUSIONS: The efficacy of early NIV in ALS should be tested in randomized, placebo-controlled trials. The trial is registered on clinicaltrials.gov (NCT00580593). CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with ALS, adherence with NIV and sham NIV are similar.
OBJECTIVE: To evaluate the use and tolerability of noninvasive positive pressure ventilation (NIV) in patients with amyotrophic lateral sclerosis (ALS) early in their disease by comparing active NIV and sham NIV in patients not yet eligible for NIV use as recommended by practice guidelines. METHODS: This was a single-center, prospective, double-blind, randomized, placebo (sham)-controlled pilot trial. Patients with ALS were randomized to receive either sham NIV or active NIV and underwent active surveillance approximately every 3 months until they reached a forced vital capacity (FVC) <50% or required NIV for clinical symptom management. RESULTS: In total, 54 participants were randomized. The mean NIV use was 2.0 hours (95% confidence interval [CI] 1.1-3.0) per day in the sham NIV treatment group and 3.3 hours (CI 2.0-4.6) per day in the active NIV group, which did not differ by treatment group (p = 0.347). The majority of sham NIV participants (88%) and active NIV participants (73%) reported only mild or no problem with NIV use. Difference of change in FVC through the treatment period by group (0.44 per month) favored active NIV (p = 0.049). Survival and changes in maximal inspiratory or expiratory pressure did not differ between treatment groups. CONCLUSIONS: The efficacy of early NIV in ALS should be tested in randomized, placebo-controlled trials. The trial is registered on clinicaltrials.gov (NCT00580593). CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with ALS, adherence with NIV and sham NIV are similar.
Authors: George W Rodway; Terri E Weaver; Cristina Mancini; Jacqueline Cater; Greg Maislin; Bethany Staley; Kathleen A Ferguson; Charles F P George; David A Schulman; Harly Greenberg; David M Rapoport; Joyce A Walsleben; Teofilo Lee-Chiong; Samuel T Kuna Journal: Sleep Date: 2010-02 Impact factor: 5.849
Authors: Devin L Brown; Ronald D Chervin; John D Kalbfleisch; Michael J Zupancic; Erin M Migda; Anna Svatikova; Maryann Concannon; Cory Martin; Kevin J Weatherwax; Lewis B Morgenstern Journal: J Stroke Cerebrovasc Dis Date: 2011-07-23 Impact factor: 2.136
Authors: R G Miller; C E Jackson; E J Kasarskis; J D England; D Forshew; W Johnston; S Kalra; J S Katz; H Mitsumoto; J Rosenfeld; C Shoesmith; M J Strong; S C Woolley Journal: Neurology Date: 2009-10-13 Impact factor: 9.910
Authors: Tanmay S Panchabhai; Eduardo Mireles Cabodevila; Erik P Pioro; Xiaofeng Wang; Xiaozhen Han; Loutfi S Aboussouan Journal: ERJ Open Res Date: 2019-09-25
Authors: Jochem Helleman; Esther T Kruitwagen-van Reenen; J Bakers; Willeke J Kruithof; Annerieke C van Groenestijn; Rineke J H Jaspers Focks; Arthur de Grund; Leonard H van den Berg; Johanna M A Visser-Meily; Anita Beelen Journal: J Neurol Date: 2020-06-23 Impact factor: 4.849